Universitat de Lleida
    • English
    • català
    • español
  • English 
    • English
    • català
    • español
  • Login
Repositori Obert UdL
View Item 
  •   Home
  • Recerca
  • Medicina
  • Articles publicats (Medicina)
  • View Item
  •   Home
  • Recerca
  • Medicina
  • Articles publicats (Medicina)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

Thumbnail
View/Open
Postprint (377.5Kb)
Issue date
2016-07-31
Author
Bover, Jordi
Ureña-Torres, Pablo
Lloret, María Jesús
Ruiz, C.
DaSilva, I.
Diaz-Encarnacion, MM.
Mercado, C.
Mateu, S.
Fernández i Giráldez, Elvira
Ballarín, José
Suggested citation
Bover, Jordi; Ureña-Torres, Pablo; Lloret, María Jesús; Ruiz, C.; DaSilva, I.; Diaz-Encarnacion, MM.; ... Ballarín, José. (2016) . Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Opinion On Pharmacotherapy, 2016, vol. 17, num. 10, p. 1363-1373. https://doi.org/10.1080/14656566.2016.1182985.
Impact


Web of Science logo    citations in Web of Science

Scopus logo    citations in Scopus

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are associated with costly complications and dismal hard-outcomes. AREAS COVERED: In two comprehensive articles we review contemporary and future pharmacological options for treatment of phosphate (P) imbalance (part 1) and hyperparathyroidism (this part 2), taking into account CKD-accelerated cardiovascular calcification (CVC) processes. EXPERT OPINION: Improvements in CKD-MBD require an integral approach, addressing all three components of the CKD-MBD triad. Here, initial guidance to control hyperparathyroidism is provided, taking into account the presence/absence of CVC. We include also measures for patients at risk of adynamic bone disease or suffering from calciphylaxis. Many epidemiological studies (relating to vitamin D) and thorough analyses of recent randomized clinical trials (of cinacalcet) point towards benefits of attempting to improve biochemical parameters while trying to, at least, avoid progression of CVC by more rational use of intestinal P-binders and low-dose vitamin D derivatives and/or calcimimetics. This approach does not seem to be far away from significantly improving hard-outcomes, at least in the dialysis population. The availability of new drugs and the performance of randomized clinical trials should ultimately lead to define earlier, clearer, and more cost-effective patient stratification and biochemical targets with consequent significant clinical improvements.
URI
http://hdl.handle.net/10459.1/63215
DOI
https://doi.org/10.1080/14656566.2016.1182985
Is part of
Expert Opinion On Pharmacotherapy, 2016, vol. 17, num. 10, p. 1363-1373
European research projects
Collections
  • Articles publicats (Medicina) [469]
  • Articles publicats (IRBLleida) [1083]

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to 
 

 

Browse

All of the repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

View Usage Statistics

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to